DBV - Invesco DB G10 Currency Harvest

NYSEArca - NYSEArca Delayed Price. Currency in USD
24.75
0.00 (0.00%)
At close: 3:32PM EST
Stock chart is not supported by your current browser
Previous Close24.75
Open24.64
Bid0.00 x 1300
Ask0.00 x 1100
Day's Range24.60 - 24.75
52 Week Range21.17 - 25.50
Volume2
Avg. Volume2,604
Net Assets24.47M
NAV24.47
PE Ratio (TTM)N/A
Yield0.08%
YTD Return3.25%
Beta (3Y Monthly)6.34
Expense Ratio (net)0.78%
Inception Date2006-09-18
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

    Montrouge, France, November 9, 2018 DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the.

  • GlobeNewswire15 days ago

    DBV Technologies Reports September 30, 2018 Cash Position

    Montrouge, France, October 30, 2018 DBV Technologies Reports September 30, 2018 Cash Position DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock.

  • GlobeNewswire19 days ago

    DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers

    DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in Part B of the EPITOPE (EPIT in TOddlers with PEanut Allergy) trial. EPITOPE is a two-part, pivotal Phase III clinical trial assessing the safety and efficacy of Viaskin Peanut 250 µg for the treatment of peanut-allergic toddlers one to three years of age.

  • GlobeNewswire23 days ago

    DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration

    DBV Technologies (Euronext: DB - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. Viaskin Peanut is the Company's lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system through the skin.

  • GlobeNewswire2 months ago

    DBV Technologies to Present at the Cantor Global Healthcare Conference

    Montrouge, France, September 25, 2018 DBV Technologies to Present at the Cantor Global Healthcare Conference DBV Technologies (Euronext: DBV - ISIN: FR0010417345 -.

  • GlobeNewswire2 months ago

    DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers

    DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the independent Data and Safety Monitoring Board (DSMB) completed its planned safety review of Part A of the EPITOPE (EPIT in TOddlers with PEanut Allergy) trial of Viaskin Peanut in peanut-allergic toddlers ages one to three. The DSMB did not identify any safety concerns for patients enrolled in Part A of the trial, recommending that the study continue as planned with the 250 µg dose selected for investigation in Part B. Following this positive DSMB recommendation, the Company plans to initiate Part B of the EPITOPE study in the fourth quarter of 2018 to assess the efficacy and safety of Viaskin Peanut 250 µg for 12 months.

  • GlobeNewswire2 months ago

    DBV Technologies : Reports First Half 2018 Financial Results

    DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2018 financial results. The interim financial report is available on the Investor Relations section of the Company's website, https://www.dbv-technologies.com/investor-relations/. First half 2018 financial statements were subject to a limited review by the Company's external auditors.

  • GlobeNewswire2 months ago

    DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI

    DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), the Geneva University Hospitals (HUG) and BioNet-Asia Co. Ltd presented new data from a Phase I study evaluating the safety and immunogenicity of boosting young adults against pertussis toxin (PT) with an investigational epicutaneous patch containing recombinant PT (Viaskin-PT). The new results, which were presented at the 5th European Congress of Immunology (ECI) in Amsterdam, Netherlands, September 2-5, 2018, by Dr. Olga Chatzis and Prof. Claire-Anne Siegrist from HUG, highlighted data from two additional cohorts showing that following skin preparation with an epidermal laser, anti-PT booster responses elicited by Viaskin-PT were comparable to those elicited by Boostrix® dTpa, an injectable approved booster vaccine.

  • GlobeNewswire2 months ago

    DBV Technologies to Attend Upcoming Investor Conferences

    DBV Technologies to Attend Upcoming Investor Conferences. DBV Technologies, a clinical-stage biopharmaceutical company, today announced that members of its management team will present and host investor ...